Clinical Trials Browser

Cholangiocarcinoma × lenvatinib × 1 year × Clear all

NCT06648057 2026-03-18

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT06859684 2026-03-09

HAIC-quad

Phase 2 Recruiting

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT07432568 2026-02-25

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

Phase 2 Not yet recruiting

Gastrointestinal

Cholangiocarcinoma

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT07070700 2025-08-12

CASTLE-ZS-02

Phase 2 Recruiting

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT03781934 2025-07-01

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

Phase 1/2 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT06643208 2025-06-26

D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC

Gastrointestinal

Cholangiocarcinoma